The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Abstract
Malignant phaeochromocytomas are rare tumours accounting for ~10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations. Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour. Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours. Although a number of recently introduced molecular markers have been explored, their clinical significance remains to be elucidated from further studies. Several imaging modalities have been utilised for the diagnosis and staging of these tumours. Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, 18 F-fluorodopamine and 18 F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies. The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion. Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using 131 I-MIBG; however, this is very rarely curative. Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect. The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving. Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Self-citationPhase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Pheochromocytoma: State-of-the-Art and Future Prospects
Bravo, E. L., & Tagle, R. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0013 · Cited by 493
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
Self-citationAverbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 346
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Ilias, I., & Pacak, K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031091 · Cited by 332
Self-citationPheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial Results
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., & Neumann, H. P. H. (2002) · Radiology · doi:10.1148/radiol.2222010622 · Cited by 325
Loh, K.-C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B., & Price, D. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348026 · Cited by 278
Kaltsas, G. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.895 · Cited by 275
Self-citationEisenhofer, G., Walther, M. M., Huynh, T.-T., Li, S.-T., Bornstein, S. R., Vortmeyer, A., Mannelli, M., Goldstein, D. S., Linehan, W. M., Lenders, J. W. M., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7496 · Cited by 267
The optimal imaging of adrenal tumours: a comparison of different methods
Ilias, I., Sahdev, A., Reznek, R. H., Grossman, A. B., & Pacak, K. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0045 · Cited by 266
Self-citationde Leon, M. P. (1994) · Recent Results in Cancer Research · doi:10.1007/978-3-642-85076-9_7 · Cited by 260
Ilias, I., Yu, J., Carrasquillo, J. A., Chen, C. C., Eisenhofer, G., Whatley, M., McElroy, B., & Pacak, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030235 · Cited by 241
Self-citationEisenhofer, G., Goldstein, D. S., Sullivan, P., Csako, G., Brouwers, F. M., Lai, E. W., Adams, K. T., & Pacak, K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2025 · Cited by 236
O'Connor, D. T., & Bernstein, K. N. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409203111204 · Cited by 228
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma
O’Riordain, D. S., Young, W. F., Grant, C. S., Carney, J. A., & van Heerden, J. A. (1996) · World Journal of Surgery · doi:10.1007/s002689900139 · Cited by 201
Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland
McNeil, A. R., Blok, B. H., Koelmeyer, T. D., Burke, M. P., & Hilton, J. M. (2000) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.2000.tb04358.x · Cited by 195
Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., et al. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01309.x · Cited by 167
Self-citationSumming up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook
Eriksson, B., & Öberg, K. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s31 · Cited by 160
High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., & Fitzgerald, P. A. (2003) · Cancer · doi:10.1002/cncr.11518 · Cited by 158
Angiogenesis and Vascular Architecture in Pheochromocytomas
Favier, J., Plouin, P., Corvol, P. L., & Gasc, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64400-8 · Cited by 156
Schlumberger, M. J., Gicquel, C., Lumbroso, J., Tenenbaum, F., Comoy, E., Bosq, J., Fonseca, E., Ghillani‐Dalbin, P., Aubert, B., Travagli, J. P., et al. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345807 · Cited by 156
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Kaltsas, G., Papadogias, D., Makras, P., & Grossman, A. B. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01116 · Cited by 145
Self-citationTenenbaum, F., Lumbroso, J., Schlumberger, M. J., Mure, A., Plouin, P., Caillou, B., & Parmentier, C. (1995) · PubMed · Cited by 139
FITZGERALD, P. A., Goldsby, R. E., Huberty, J. P., Price, D. C., Hawkins, R. A., Veatch, J., Cruz, F. S. D., Jahan, T. M., LINKER, C. A., Damon, L. E., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.050 · Cited by 127
Young, A. L., Baysal, B. E., Deb, A., & Young, W. F. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020312 · Cited by 122
Clinical management of malignant adrenal tumors
Kopf, D., Goretzki, P. E., & Lehnert, H. (2001) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320000170 · Cited by 108
Oncologic aspects of pheochromocytoma: the importance of follow-up.
Hw, S., & Halter, S. A. (1984) · PubMed · Cited by 98
Malignant Pheochromocytoma: Chromaffin Granule Transmitters and Response to Treatment
Rao, F., Keiser, H. R., & O’Connor, D. T. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.1045 · Cited by 96
Garaventa, A., Gambini, C., Villavecchia, G., Cataldo, A. D., Bertolazzi, L., Pizzitola, M. R., Bernardi, B. D., & Haupt, R. (2003) · Cancer · doi:10.1002/cncr.11167 · Cited by 95
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
Wiseman, G. A., & Kvols, L. K. (1995) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(95)80016-6 · Cited by 94
Maurea, S., Cuocolo, A., Reynolds, J. C., Neumann, R. D., & Salvatore, M. (1996) · PubMed · Cited by 89
Treatment of Malignant Pheochromocytomas With 131-I Metaiodobenzylguanidine and Chemotherapy
Sisson, J. C., Shapiro, B., Shulkin, B. L., Urba, S. G., Zempel, S., & Spaulding, S. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199908000-00008 · Cited by 87
Malignant pheochromocytoma: A series of 14 cases observed between 1966 and 1990
Mornex, R., Badet, C., & Peyrin, L. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345808 · Cited by 79
The role of chromogranin A in the management of patients with phaeochromocytoma
Grossrubatscher, E. M., Dalino, P., Vignati, F., Gambacorta, M., Pugliese, R., Boniardi, M., Rossetti, O., Marocchi, A., Bertuzzi, M., & Loli, P. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02591.x · Cited by 74
Kasperlik-Zaluska, A. A., Rosłonowska, E., Slowinska-Srzednicka, J., Otto, M., Cichocki, A. S., Ćwikła, J. B., Słapa, R. Z., & Eisenhofer, G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.004 · Cited by 71
Shapiro, B., Sisson, J. C., Wieland, D. M., Mangner, T. J., Zempel, S., Mudgett, E. E., Gross, M. D., Carey, J. E., Zasadny, K. R., & Beierwaltes, W. H. (1991) · PubMed · Cited by 71
The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma
Nativ, O., Grant, C. S., Sheps, S. G., O'Fallon, J. R., Farrow, G. M., van Heerden, J. A., & Lieber, M. M. (1992) · Cancer · doi:10.1002/1097-0142(19920601)69:11<2683::aid-cncr2820691110>3.0.co;2-m · Cited by 70
131I-MIBG therapy of neural crest tumours (review).
Troncone, L., & Rufini, V. (1997) · PubMed · Cited by 59
A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma
Pacák, K., Goldstein, D. S., Doppman, J. L., Shulkin, B. L., Udelsman, R., & Eisenhofer, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7714 · Cited by 59
Park, J., Yeh, M. W., Wong, M. G., Lobo, M., Hyun, W. C., Duh, Q., & Clark, O. H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020340 · Cited by 58
Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma
Bausch, B., Koschker, A., Faßnacht, M., Stoevesandt, J., Hoffmann, M. M., Eng, C., Allolio, B., & Neumann, H. P. H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0780 · Cited by 58
Chromogranin A in Human Neuroendocrine Tumors
Portela‐Gomes, G. M., Grimelius, L., Johansson, H., et al. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200110000-00006 · Cited by 57
Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma.
d’Herbomez, M., Gouze, V., Huglo, D. G., Calzada-Nocaudie, M., Pattou, F. N., Proye, C. A. G., Wémeau, J.-L., & Marchandise, X. (2001) · PubMed · Cited by 56
Genetic aspects of pheochromocytoma.
Koch, C. A., Vortmeyer, A. O., Sc, H., Alesci, S., Zhuang, Z., & Pacák, K. (2001) · PubMed · Cited by 54
Castellani, M. R., Chiti, A., Seregni, E. C., & Bombardieri, E. (2000) · PubMed · Cited by 52
The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours
Kaltsas, G., Mukherjee, J. J., Plowman, P. N., & Grossman, A. B. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01396.x · Cited by 51
Self-citationImaging evaluation of the non-functioning indeterminate adrenal mass
Sahdev, A., & Reznek, R. H. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.06.012 · Cited by 49
Guignat, L., Bidart, J., Nocera, M., Comoy, E., Schlumberger, M. J., & Baudin, É. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1677 · Cited by 48
Bomanji, J. B., Britton, K. E., Ur, E., Hawkins, L., Grossman, A. B., & BESSER, G. M. (1993) · Nuclear Medicine Communications · doi:10.1097/00006231-199310000-00004 · Cited by 45
Self-citationSomatostatin Analogs in Oncology: A Look to the Future
Jenkins, S. A., Kynaston, H., Davies, N. P., BAXTER, J. N., & Nott, D. (2001) · Chemotherapy · doi:10.1159/000049168 · Cited by 42
Khorram‐Manesh, A., Ahlman, H., Jansson, S. K. G., & Nilsson, O. (2002) · Endocrine Pathology · doi:10.1385/ep:13:2:099 · Cited by 41
Sisson, J. C., Shapiro, B., Hutchinson, R., Carey, J. E., Zasadny, K. R., Zempel, S., & Normolle, D. P. (1994) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00182305 · Cited by 40
Giovanella, L., Squin, N., Ghelfo, A., & Ceriani, L. (2006) · PubMed · Cited by 40
Takahashi, K., Ashizawa, N., Minami, T., Suzuki, S., Sakamoto, I., Hayashi, K., Tomiyasu, S., Sumikawa, K., Kitamura, K., Eto, T., et al. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.349 · Cited by 39
Portela‐Gomes, G. M., Stridsberg, M., Grimelius, L., Falkmer, S., & Falkmer, S. (2004) · Apmis · doi:10.1111/j.1600-0463.2004.t01-1-apm1121005.x · Cited by 38
Hartley, A. G. J., Spooner, D. A., & Brunt, A. M. (2001) · Clinical Oncology · doi:10.1053/clon.2001.9290 · Cited by 37
Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas
Moreno‐Fernández, A. M., Castilla‐Guerra, L., Martínez-Torres, M. C., Torres-Olivera, F., Fernández, E., & Galera-Davidson, H. (1999) · Neuropeptides · doi:10.1054/npep.1999.0012 · Cited by 34
Amar, L., Peyrard, S., Rossignol, P., Zinzindohoué, F., Gimenez‐Roqueplo, A., & Plouin, P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.042 · Cited by 33
Pediatric malignant pheochromocytoma
Ein, S. H., Weitzman, S. S., Thorner, P. S., Seagram, C. G. F., & Filler, R. M. (1994) · Journal of Pediatric Surgery · doi:10.1016/0022-3468(94)90799-4 · Cited by 33
Molecular and immunohistochemical analysis of P53 in phaeochromocytoma
Dahia, P., Aguiar, R., Tsanaclis, A. M. C., Bendit, I., Bydlowski, S. P., Abelin, N. M. A., & Toledo, S. P. A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.487 · Cited by 31
Treatment of Metastatic Pheochromocytoma and Paraganglioma With 131I-Meta-Iodobenzylguanidine (MIBG)
Kaltsas, G., Mukherjee, J. J., Foley, R., Britton, K. E., & Grossman, A. B. (2003) · The Endocrinologist · doi:10.1097/01.ten.0000084154.02341.ad · Cited by 27
Self-citationTada, K., Okuda, Y., & Yamashita, K. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023190 · Cited by 23
Pujol, P., Bringer, J., Faurous, P., et al. (1995) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00941856 · Cited by 23
131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma
Sakahara, H., Endo, K., Saga, T., Hosono, M., Kobayashi, H., & Konishi, J. (1994) · Annals of Nuclear Medicine · doi:10.1007/bf03165018 · Cited by 22
Wu, L., Dicpinigaitis, P. V., Bruckner, H. W., Manger, W. M., & Averbuch, S. D. (1994) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950220607 · Cited by 22
[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.
Lumbroso, J., Schlumberger, M. J., Tenenbaum, F., Aubert, B. S., Travagli, J. P., & Parmentier, C. (1991) · PubMed · Cited by 20
Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma.
Lewington, V. J., Ma, Z., Tristam, M., Aj, M., & Dm, A. (1991) · PubMed · Cited by 19
[131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
Ca, H., Schornagel, J. H., & Olmos, V. S. (1991) · PubMed · Cited by 19
I-123 MIBG Imaging and Intraoperative Localization of Metastatic Pheochromocytoma: A Case Report
Buhl, T., Mortensen, J., & Kjær, A. (2002) · Clinical Nuclear Medicine · doi:10.1097/00003072-200203000-00007 · Cited by 18
A Phenotypic Perspective on Mammalian Oxygen Sensor Candidates
Baysal, B. E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.024 · Cited by 17
Radionuclide therapy of malignant pheochromocytoma with131I-MIBG
Nakabeppu, Y., & Nakajo, M. (1994) · Annals of Nuclear Medicine · doi:10.1007/bf03165029 · Cited by 15
Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine.
Fischer, M. (1991) · PubMed · Cited by 15
Lawrence, J., Maher, E. R., Sheaves, R., & Grossman, A. B. (2004) · HORMONES · doi:10.14310/horm.2002.11121 · Cited by 13
Self-citationPalliative Chemotherapy for Malignant Pheochromocytoma: Symptomatic Palliation of Two Cases.
Iwabuchi, M., Oki, Y., & Nakamura, H. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.433 · Cited by 11
Pheochromocytoma: An Update on Risk Groups, Diagnosis, and Management
Nguyen-Martin, M. A., & Hammer, G. D. (2006) · Cited by 11
Colombo, L., Lomuscio, G., Vignati, A., & Dottorini, M. E. (1991) · PubMed · Cited by 10
Schvartz, C., Gibold, C., Vuillemin, B., & Mj, D. (1991) · PubMed · Cited by 6
Cited by
Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W. M., Lussey-Lepoutre, C., Steichen, O., & _, _. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0033 · Cited by 480
Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1946 · Cited by 428
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
Koh, J.-M., Ahn, S. H., Kim, H., Kim, B.-J., Sung, T.-Y., Kim, Y. H., Hong, S. J., Song, D. E., & Lee, S. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187398 · Cited by 114
Metadata
- Authors
- Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2007-09
- Volume
- 14
- Issue
- 3
- Pages
- 569-585
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2107966316
- Cited by
- 314
- References
- 82
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.